-
TRIALMAP: AN END-TO-END SOLUTION FOR MODERN CLINICAL TRIALS DESIGN WITH RWD AND AI
Mar 18, 2026, 21:38 PM -
PROMISE OF REAL-WORLD DATA NETWORKS: INNOVATIONS IN TRIAL DESIGN USING PCORNET®
Mar 18, 2026, 21:38 PM -
ASSOCIATION OF MARIJUANA USE AND HEALTH-RELATED QUALITY OF LIFE AMONG CARDIOVASCULAR DISEASE PATIENTS. EVIDENCE FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM
Mar 18, 2026, 21:38 PM -
DIGITAL TOOL FOR TECHNICAL EVALUATION OF SINGLE-USE MEDICAL DEVICES IN MERCOSUR PUBLIC PROCUREMENT
Mar 18, 2026, 21:38 PM -
FACTORS ASSOCIATED WITH HEALTHCARE COSTS AND DISEASE PROGRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS IN THE US REAL-WORLD SETTING
Mar 18, 2026, 21:38 PM -
PCV20 FOR HIGH-RISK POPULATIONS: A COST-UTILITY ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Mar 18, 2026, 21:38 PM -
IMPACT OF LUPUS NEPHRITIS FLARES ON HEALTHCARE UTILIZATION: A RETROSPECTIVE COHORT STUDY IN THE UNITED STATES BETWEEN 2016 AND 2025
Mar 18, 2026, 21:38 PM -
INTEGRATING GENERATIVE ARTIFICIAL INTELLIGENCE (AI) INTO BIOSTATISTICAL WORKFLOWS FOR TRIAL EMULATION: A FRAMEWORK TO ACCELERATE REAL-WORLD EVIDENCE GENERATION
Mar 18, 2026, 21:38 PM -
COMPARATIVE POST-MARKETING SAFETY STUDY OF NIRSEVIMAB AND PALIVIZUMAB: A PHARMACOVIGILANCE ANALYSIS USING FAERS AND WHO VIGIACCESS
Mar 18, 2026, 21:38 PM -
EQ-5D BASED UTILITY VALUES BY CLINICAL RESPONSE AND SYMPTOM SEVERITY IN JAPANESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: POST-HOC ANALYSIS OF JAPANESE BREXPIPRAZOLE CLINICAL TRIALS
Mar 18, 2026, 21:38 PM -
PREDICTING OVERALL SURVIVALIN NON-SMALL CELL LUNG CANCER PATIENTSRECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPYUSING A JOINT MODEL INTEGRATING SERIAL GENETIC AND EPIGENETIC BIOMARKERS
Mar 18, 2026, 21:38 PM -
CONTENT VALIDITY OF THE EQ-HWB-9 IN PATIENTS WITH ADVANCED ILLNESSES: A COGNITIVE DEBRIEFING STUDY
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG WOMEN WITH VASOMOTOR SYMPTOMS (VMS) WITH AND WITHOUT DEPRESSION: A MEPS ANALYSIS
Mar 18, 2026, 21:38 PM -
HAVE PFDD MEETINGS MEANINGFULLY INFORMED NDA AND BLA REVIEWS BY THE CENTER FOR DRUG EVALUATION AND RESEARCH? FINDINGS FROM ANALYSIS OF PRODUCTS APPROVED FROM JUNE 2017 TO DECEMBER 2025
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING-BASED PREDICTION OF 10-YEAR CORONARY HEART DISEASE RISK AND COMPARISON WITH THE FRAMINGHAM RISK SCORE
Mar 18, 2026, 21:38 PM -
MEDICAID DRUG REBATE AND SAVINGS IMPLICATIONS OF MOST FAVORED NATION PRICING UNDER THE GENEROUS MEDICAID MODEL
Mar 18, 2026, 21:38 PM -
DETECTING SAFETY SIGNALS OF BILE ACID THERAPEUTICS: A FDA FAERS-BASED PHARMACOVIGILANCE STUDY
Mar 18, 2026, 21:38 PM -
TYPE 1 AND TYPE 2 DIABETES MELLITUS IDENTIFICATION USING ICD-10-CM CODES AMONG NEW USERS OF ANTIDIABETICS: A REAL-WORLD STUDY FROM KOMODO RESEARCH DATASET
Mar 18, 2026, 21:38 PM -
EVIDENCE GENERATION RECOMMENDATIONS TO SUPPORT GLOBAL PHARMACEUTICAL LAUNCHES FOLLOWING MAJOR POLICY CHANGES IN THE US (INFLATION REDUCTION ACT AND MOST FAVORED NATION) AND EU (JOINT CLINICAL ASSESSMENTS)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS AND ACCESS CONSIDERATIONS FOR GLP-1-BASED THERAPIES IN TYPE 2 DIABETES AND OBESITY: INSIGHTS FROM US PAYER AND HTA PERSPECTIVES
Mar 18, 2026, 21:38 PM
